



**World Health
Organization**

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus



Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

ISBN 978-92-4-155028-4

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus. Geneva: World Health Organization; 2018. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Abbreviations	3
Glossary	4
Executive summary	6
1. Introduction	8
1.1 Scope and aim of guidelines	9
1.2 Target audience	10
2. Methods for developing the guidelines	10
2.1 Guideline contributors	10
2.2 Outcome rating	10
2.3 Reviews of evidence	10
2.4 Quality of evidence and strength of recommendations	11
2.5 Deciding upon recommendations	12
2.6. Funding	13
3. Recommendations	13
3.1. Hypoglycaemic agents for second-line treatment in type 2 diabetes	13
3.1.1 Summary of the evidence	13
3.1.2 Rationale for the recommendation	14
3.2. Hypoglycaemic agents for third-line treatment in type 2 diabetes	16
3.2.1 Summary of evidence	16
3.2.2 Rationale for the recommendation	16
3.2.6 Feasibility	17
3.3 Insulin	18
3.3.1 Summary of the evidence	18
3.3.2 Rationale for the recommendations	20
4. Research gaps	21
4.1 Oral hypoglycaemic agents	21

4.2 Insulin	22
5. Publication, implementation and evaluation	22
5.1 Publication	22
5.2 Implementation and dissemination.....	22
5.3 Evaluation	22
5.4 Future updating of the guideline	23
References	24
Appendix 1. Acknowledgements	27
Appendix 2. Managing declarations of interest and conflicts of interest.....	29
Appendix 3: PICO questions and ranked outcomes.....	30
Appendix 4. Methods for identification of recent high-quality systematic reviews	34
Appendix 5. Hypoglycaemic agents for second-line treatment in type 2 diabetes.....	37
Appendix 6. Price of Defined Daily Dose of medications for treatment of type 2 diabetes, compared to sulfonylurea	41
Appendix 7: Cost-effectiveness of medicines to treat Type 1 and Type 2 diabetes: a narrative review of the published literature	42
Appendix 8. Reviews of patient treatment preferences.....	45
Appendix 9. Hypoglycaemic agents for third-line treatment in type 2 diabetes.....	58
Appendix 10. Long-acting insulin analogues – summary of findings tables for critical outcomes	61
Appendix 11. Short-acting insulin analogues – summary of findings tables for critical outcomes	67

Abbreviations

CDC	Centers for Disease Control and Prevention
CI	confidence interval
CrI	credibility interval
COI	conflict of interest
CVD	cardiovascular disease
DOI	declaration of interest
DPP-4 inhibitors	dipeptidyl peptidase-4 inhibitors
EMA	European Medicines Agency
EML	Essential Medicines List
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HbA1c	glycated haemoglobin A1c
IDF	International Diabetes Federation
PICO	population – intervention – comparator – outcome
MET	metformin
MI	myocardial infarction
NICE	National Institute for Health and Care Excellence
NMA	network meta-analysis
NPH	neutral protamine hagedorn
OHA	oral hypoglycaemic agents
RCT	randomized controlled trial
RHI	regular human insulin
SIGN	Scottish Intercollegiate Guidelines Network
SGLT-2 inhibitor	sodium-glucose co-transporters type 2 inhibitors
SU	sulfonylureas
TZDs	thiazolidinediones (glitazones)
UHC	universal health coverage
WHO PEN	<i>WHO Package of Essential Non-Communicable Disease (NCD) Interventions</i> for primary care in low-resource settings

Glossary

Cardiovascular diseases (CVDs)

A group of disorders of the heart and blood vessels that include coronary heart disease and cerebrovascular disease.

Diabetic ketoacidosis and hyperosmolar hyperglycaemia

Life-threatening conditions characterized by fluid and electrolyte depletion, high blood glucose levels and metabolic acidosis (metabolic acidosis may be absent in hyperosmolar hyperglycaemia).

Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors or gliptins)

Oral hypoglycaemic agents used in treating type 2 diabetes. They suppress the degradation of incretins by blocking the action of the enzyme dipeptidyl-peptidase 4. This stimulates insulin secretion and suppresses glucagon release.

HbA1c

Haemoglobin glycosylated by non-enzymatic attachment of glucose to haemoglobin. The concentration of HbA1c is the most commonly used measure of chronic glycaemia in clinical trials and diabetes management. It is considered to reflect the integrated mean glucose level over the previous 8–12 weeks.

Hypoglycaemia

Potentially life-threatening low concentration of blood glucose, most frequently a side-effect of pharmacological treatment. There is no universally agreed definition. In studies the definitions of hypoglycaemia are most frequently in the range <4 mmol/L to ≤ 2.8 mmol/L. Severe hypoglycaemia is most frequently defined as a symptomatic condition that requires the assistance of a third person for resuscitative actions.

Insulin analogues

Insulins different from any occurring in nature and derived from human insulin by modifying its structure to change the pharmacokinetic profile.

Metformin

A biguanide oral hypoglycemic agent used in treating type 2 diabetes. It decreases glucose production by the liver and increases the insulin sensitivity of body tissues.

Neutral Protamine Hagedorn (NPH or isophane) insulin

An intermediate-acting insulin preparation used in type 1 and type 2 diabetes. It is produced by crystallizing zinc-insulin-protamines at neutral pH. It is called neutral protamine Hagedorn for inventor Hans Christian Hagedorn.

Sodium-glucose co-transporters type 2 inhibitors (SGLT-2 inhibitors)

Oral hypoglycaemic agents used in treating type 2 diabetes. They lower blood glucose by causing the kidneys to remove glucose from the body through the urine.

Sulfonylureas

Oral hypoglycemic agents used in treating type 2 diabetes. They stimulate insulin secretion by the pancreas.

Thiazolidinediones (glitazones)

Oral hypoglycaemic agents used in treating type 2 diabetes. They work by lowering insulin resistance – a core physiologic defect in those with type 2 diabetes.

Type 1 diabetes

Diabetes caused by the destruction of pancreatic beta-cells, resulting in lack of insulin production by the pancreas and need for insulin injections for survival.

Type 2 diabetes

Diabetes characterized by various degrees of disorders of insulin action in the body and insulin secretion by the pancreas. Insulin injections are not needed for survival, but might be needed for controlling blood glucose levels.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_25906

